7 Most Volatile Stocks Under $5 for Day Trading

5. C4 Therapeutics, Inc. (NASDAQ:CCCC)

Number of Hedge Fund Holders: 21

C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading.

As of February 16, 2026, all of the analysts who cover C4 Therapeutics, Inc. (NASDAQ:CCCC) remain bullish on the stock. Their consensus price target of $7.00 indicates a 270.37% upside, which reflects their belief in Cemsidomide, the company’s primary degrader.

On January 14, 2026, C4 Therapeutics, Inc. (NASDAQ:CCCC) laid out key clinical and regulatory milestones through 2028, including plans to achieve accelerated approval for Cemsidomide in relapsed/refractory multiple myeloma.

With an NDA submission targeted by year-end 2028 and initial ORR data anticipated in 2H 2027, C4 Therapeutics, Inc. (NASDAQ:CCCC) intends to launch the Phase 2 MOMENTUM trial in Q1 2026 for patients who are fourth-line or later. In patients with second-line or later disease, a Phase 1b combination study involving elranatamab is scheduled to start in Q2 2026, while a Phase 3 trial is anticipated by early 2028.

Based on 2025 Phase 1 data, Cemsidomide showed ORRs of 40% and 53% at 75 µg and 100 µg, respectively. With partnerships with Merck KGaA, Roche, and Biogen, C4T hopes to file up to 3 INDs by 2028 from its neuro- and inflammation programs, in addition to its oncology programs.

C4 Therapeutics, Inc. (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, uses its Degronimid platform to develop small-molecule degraders that selectively eliminate disease-driving proteins in neurodegenerative, inflammatory, and cancerous diseases.